Clinical Trial Update: Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase IIa randomized, placebo-controlled trial evaluating mesenchymal stem cells as a disease-modifying therapy for Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED